TriangleMetformin Hydrochloride ER (NCT07291297)
Metformin Hydrochloride ER trial for Sarcoma Metastatic (NCT07291297). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with unresectable or metastatic intermediate/high-grade soft-tissue sarcoma starting first-line systemic treatment. Metformin use at diagnosis or brain metastases excludes participation.
The idea: metformin alters cellular energy signaling and may interfere with tumor-growth pathways. Researchers add it to physician-selected standard treatment and measure survival at twelve months. Oral dosing starts at 1000 milligrams daily for fourteen days, increasing to twice daily only if tolerated. Treatment can continue up to five years.
This phase 2 study plans 50 patients. Megan Jagosky leads at Wake Forest; two North Carolina sites recruit.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.